Table 1.

The EGFR-KDD is a recurrent alteration

DatasetIdentification #AgeGenderReported diagnosis
Foundation MedicineFM-152FemaleLung adenocarcinoma
FM-2a33MaleLung adenocarcinoma
FM-353FemaleLung adenocarcinoma
FM-457FemaleLung adenocarcinoma
FM-529FemaleLung NSCLC (NOS)
FM-653FemaleBrain astrocytoma
FM-749MaleBrain glioblastoma
FM-854MaleBrain glioblastoma
FM-92FemaleKidney Wilms' tumor
FM-1063FemalePeritoneal serous carcinoma
FM-1127FemaleSoft tissue sarcoma (NOS)
TCGATCGA-49-451269MaleLung adenocarcinoma
TCGA-12-082162FemaleBrain glioblastoma
MSKCCMSKCC-1a33MaleLung adenocarcinoma
MSKCC-267FemaleLung adenocarcinoma
MSKCC-3b53MaleBrain glioblastoma

NOTE: Characteristics of EGFR-KDD exons 18–25 patients from Foundation Medicine, TCGA, and Memorial Sloan Kettering Cancer Center datasets.

Abbreviation: NOS, not otherwise specified.

a, index patient; b, this patient's tumor also contained high level amplification of EGFRWT and an EGFRG719C mutation. The EGFR-KDD and EGFRG719C alterations were below the level of EGFRWT amplification, and presumably reflect subclonal populations.